Flossbach Von Storch SE Purchases 78,428 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Flossbach Von Storch SE increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 16.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 551,764 shares of the company's stock after acquiring an additional 78,428 shares during the quarter. IDEXX Laboratories makes up 1.0% of Flossbach Von Storch SE's portfolio, making the stock its 28th biggest position. Flossbach Von Storch SE owned 0.68% of IDEXX Laboratories worth $231,713,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of IDXX. Ninety One SA PTY Ltd raised its stake in IDEXX Laboratories by 34.8% during the first quarter. Ninety One SA PTY Ltd now owns 6,008 shares of the company's stock valued at $2,523,000 after buying an additional 1,551 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in IDEXX Laboratories by 32.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 2,749 shares of the company's stock valued at $1,154,000 after buying an additional 676 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in IDEXX Laboratories by 1.6% during the first quarter. Crossmark Global Holdings Inc. now owns 3,768 shares of the company's stock valued at $1,582,000 after buying an additional 59 shares in the last quarter. Pacific Point Advisors LLC raised its stake in IDEXX Laboratories by 8.6% during the first quarter. Pacific Point Advisors LLC now owns 3,457 shares of the company's stock valued at $1,452,000 after buying an additional 274 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in IDEXX Laboratories by 8.2% during the first quarter. Envestnet Asset Management Inc. now owns 161,829 shares of the company's stock valued at $67,960,000 after buying an additional 12,255 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the sale, the director directly owned 1,801 shares in the company, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IDXX. Leerink Partners upped their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Jefferies Financial Group began coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price for the company. Finally, Stifel Nicolaus upped their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a report on Wednesday, July 2nd. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $558.11.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded up $2.64 during trading hours on Thursday, hitting $543.28. 100,631 shares of the stock were exchanged, compared to its average volume of 728,303. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The stock has a market capitalization of $43.69 billion, a P/E ratio of 50.23, a P/E/G ratio of 3.93 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $549.52. The business's 50-day moving average is $517.06 and its two-hundred day moving average is $457.26.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the prior year, the business earned $2.71 earnings per share. IDEXX Laboratories's quarterly revenue was up 3.6% on a year-over-year basis. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.